Page 117 | Certara

Blog

The Growing Value of Quantitative Systems Pharmacology (QSP)

Gain a foundational understanding of QSP in this 101-level article with examples of QSP applied…

CertaraOctober 7, 2022

On-Demand Webinar

How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing

Historically, the dosing strategy for oncology drugs focused on the maximum tolerated dose. This has…

CertaraOctober 5, 2022

Blog

Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist

Choosing the right technology and services vendor to support your organization’s transparency and disclosure (T&D)…

CertaraOctober 4, 2022

Blog

5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results

For the first time, the European Medicines Agency (EMA) has passed new regulations to help…

CertaraSeptember 27, 2022

Business transparency, integrity or data disclosure concept, businessman standing with disclosure financial document in crystal clear fish bowl

Blog

EU-CTR Challenges Drug Developers Faced in the First 6 Months

Under European Union Clinical Trial Regulation 536/2014 (EU-CTR), replacing the EU Clinical Trial Directive (Directive…

CertaraSeptember 26, 2022

Podcast

Certara – Improving Investment in Drug Development through Biosimulation

CertaraSeptember 23, 2022

On-Demand Webinar

Optimize drug development with public data and predictive models – model-based meta-analysis (MBMA)

Properly understanding the probability of successful drug development requires utilization of all available information. Critical…

CertaraSeptember 23, 2022

Blog

3 Takeaways from the FDA Oligo Guidance You Need to Know

In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…

CertaraSeptember 23, 2022

On-Demand Webinar

Pinnacle 21 Data Exchange: Transforming External Vendor Data Management

The volume and complexity of clinical data are growing at a faster pace than the…

CertaraSeptember 19, 2022

Fact Sheet

Accelerating Pediatric Drug Development with Biosimulation and Regulatory Science

CertaraSeptember 13, 2022

The Growing Value of Quantitative Systems Pharmacology (QSP)

How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing

Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist

5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results

EU-CTR Challenges Drug Developers Faced in the First 6 Months

Certara – Improving Investment in Drug Development through Biosimulation

Optimize drug development with public data and predictive models – model-based meta-analysis (MBMA)

3 Takeaways from the FDA Oligo Guidance You Need to Know

Pinnacle 21 Data Exchange: Transforming External Vendor Data Management

Accelerating Pediatric Drug Development with Biosimulation and Regulatory Science

Newsletter sign up

Quick links

Solutions

Contact